Asset profile
XEN-D0501
Small molecule
Evidence outlook · lead readout
NCT05353686 · Efficacy, Safety, Pharmacokinetics, Diabetes Mellitus, Type 2
The lead readout missed its primary endpoint. The grade and rationale below record what the trial was designed to show and what it found.
NCT05353686: The study was a randomized, triple-blind, placebo-controlled parallel-group trial involving 54 participants. Its primary endpoint was fasting blood glucose, a surrogate measure, and the outcome cannot be classified as met or missed because results are not available.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
61 competitors in this universe: 0 direct rivals (same mechanism and indication), 1 same-class, 60 same-indication; 61 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| XEN-D0501: this drug | Phase 2 | Small molecule | TRPV1 | ||
| Asivatrep | Phase 3 | Small molecule | TRPV1 | ||
| Afrezza | Approved | Peptide | Insulin receptor (basal), Insulin | ||
| Alogliptin (Nesina) | Approved | Small molecule | DPP-4 | ||
| Bexagliflozin (Brenzavvy) | Approved | Small molecule | SGLT2 | ||
| Canagliflozin (Invokana) | Approved | Small molecule | SGLT2 | ||
| Dapagliflozin (Farxiga / Forxiga) | Approved | Small molecule | SGLT2 | ||
| Dulaglutide (Trulicity) | Approved | Peptide | GLP-1 receptor | ||
| Empagliflozin (Jardiance) | Approved | Small molecule | SGLT2 | ||
| Ertugliflozin (Steglatro) | Approved | Small molecule | SGLT2 | ||
| Glipizide (Glucotrol) | Approved | Small molecule | Sulfonylurea receptor (SUR1) | ||
| Glyburide (Diabeta / Micronase) | Approved | Small molecule | Sulfonylurea receptor (SUR1) | ||
| Insulin Aspart (NovoLog / Fiasp) | Approved | Peptide | Insulin receptor | ||
| Insulin Degludec (Tresiba) | Approved | Peptide | Insulin receptor (basal) | ||
| Insulin Detemir (Levemir) | Approved | Peptide | Insulin receptor (basal) | ||
| Insulin Glargine (Lantus / Toujeo) | Approved | Peptide | Insulin receptor (basal) |
…and 46 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.